ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.
Follow PRPH
ProPhase Labs, Inc. (PRPH) EV/Sales
As of 16 October 2026, ProPhase Labs, Inc. (PRPH) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from −107× (October 2024) to 14.5× (July 2024); the current reading is higher than 49% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (53.58%) |
| FY2024 | 4.7× | 84.98% |
| FY2023 | 2.6× | 128.73% |
| FY2022 | 1.1× | (13.48%) |
| FY2021 | 1.3× | (82.71%) |
| FY2020 | 7.5× | 202.25% |
| FY2019 | 2.5× | 5.84% |
| FY2018 | 2.3× | 44.85% |
| FY2017 | 1.6× | (81.79%) |
| FY2016 | 8.8× | (8.73%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.2× | 7.14% |
| Mar 2026 | 2.0× | (6.73%) |
| Dec 2025 | 2.2× | (46.27%) |
| Sep 2025 | 4.1× | 9.71% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| AWHL Aspira Women's Health Inc. compare | 1.4× |
| NOTVQ Inotiv, Inc. compare | 1.6× |
| PRPH ProPhase Labs, Inc. | 1.8× |
| NDRA ENDRA Life Sciences Inc. compare | 2.2× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)